Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results for quarter ended March 31, 2026.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued April 29, 2026
- Detailed results furnished in Exhibit 99.1 for investor review
Item 7.01 · Regulation FD Disclosure
- Q1 2026 supplemental business and financial information furnished as Exhibit 99.2
- Investor relevance: additional operating and financial detail beyond the core 8-K disclosure
- Quarterly Summary available through Glaukos’ investor-relations “Financials & Filings” section
Item EX-99.1 · Exhibit EX-99.1
- Q1 net sales reached $150.6M, up 41% reported and 39% constant currency, signaling accelerating commercial momentum
- Glaucoma sales rose 47% to $129.3M, with U.S. sales up 58% to $93.5M
- Gross margin improved to 77.9% from 77.2%; non-GAAP margin expanded to 83.6% from 82.4%
- Non-GAAP operating loss narrowed to $10.5M from $15.2M despite SG&A and R&D increases
- 2026 sales guidance raised to $620M-$635M from $600M-$620M, supported by iDose TR and Epioxa growth drivers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.